Consumo de antimicrobianos parenterales en diferentes hospitales de Chile durante el año 2005

Abstract

Intravenous antimicrobial use among different hospital in Chile during 2005Intravenous antimicrobial consumption has not been evaluated previously in Chile. In order to know this consumption (in DDD per 100 bed days), associated factors and antimicrobial control systems across the country, a questionnaire was sent to evaluate these features during 2005. A total of 29 public hospitals and private clinics answered this poll, 20 belonging to the public health system (69%). Only 48.1% declared to have an independent antimicrobial committee and 17.2% allowed unrestricted antimicrobial use. Glycopeptides and carbapenems were the most regulated compounds (75.9 and 82.8%, respectively). Antimicrobial controls systems were more frequently declared among public hospitals and only non-public hospitals permitted free use of antimicrobials. Global consumption reached 59.98 DDD per 100 bed-days, with beta-lactams representing 74.3% of this consume (44.57 DDD per 100), and cephalosporins 43% (25.78 DDD per 100). Chloramphenicol, penicillin G and cloxacillin use was significantly higher among public hospitals. The opposite was observed for imipenem-cilastatin, linezolid, cefuroxime and caspofungin with higher consumes observed among nonpublic hospitals. In a multivariate analysis, increased cefazolin use was independently associated with sites allowing unrestricted use, and ciprofloxacin consumption with non-public hospitals. Institutions with decreased susceptibility to imipenem-cilastatin among non-fermentative gram negative bacilli showed a higher use of this compound and linezolid consumption paralleled vancomycin-resistant enterococci prevalence. It is necessary to reinforce governmental regulations about antimicrobial use issued during 1999.

Consumo de antibacterianos en tres hospitales de Santiago de Cuba en el período 2019-2020

“…En los hospitales las infecciones son cada día más difíciles de tratar por lo que un número elevado de pacientes recibe tratamiento con AB (Angles, 2018;Fica, 2008;Vega et al, 2015). Además, se ha observado que la mitad de las prescripciones son inadecuadas, que el consumo es elevado y su uso irracional; lo que ha contribuido a que existan altas tasas de resistencia bacteriana (Fleming-Dutra et al, 2016;Nathwani et al, 2019).…”

Cambios en las prescripciones y el consumo de antimicrobianos, luego de la implementación de recomendaciones de uso: experiencia en un hospital universitario

“…En nuestro país, para el año 2008 ceftriaxona fue el AM más consumido en el medio hospitalario, representando diariamente cerca de 18 tratamientos por cada 100 camas ocupadas. Ciprofloxacina registró valores promedio de 0,68 DDD/100 día/cama 23 . En nuestro centro, el año 2013 el consumo de ceftriaxona fue de 8,4 DDD/100 días cama, mientras que ciprofloxacina y levofloxacina fueron de 2,54 y 1,86 DDD/100 camas día respectivamente.…”

Long-term impact of competitive biddings and an antimicrobial stewardship program in a general hospital in Chile

“…5 unidad Bioestadística. 6 A ntimicrobial control is imperative due to emergence of resistant isolates, shortage of therapeutic drugs, risk of clinical failure and mortality, and expenditure increases 1,2 . Recently, a global program has been issued by WHO asking to adopt different strategies to control this threat 3 .…”

“…These interventions require financial investment to hire human resources, and support differente activities. Chile has a governmental regulation issued by the Ministry of Health since 1999 in order to implement antimicrobial stewardship programs (ASP) in hospitals that has never been supervised, and studies developed more a decade ago showed partial fulfillment 6 . Literature on the impact of ASP in Chile is scarce 7,8 and probably explained by the low number and the geographically concentrated distribution of infectious diseases (ID) specialists.…”